| pubmed-article:12637317 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12637317 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12637317 | lifeskim:mentions | umls-concept:C0023473 | lld:lifeskim |
| pubmed-article:12637317 | lifeskim:mentions | umls-concept:C0939537 | lld:lifeskim |
| pubmed-article:12637317 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:12637317 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:12637317 | lifeskim:mentions | umls-concept:C0231174 | lld:lifeskim |
| pubmed-article:12637317 | lifeskim:mentions | umls-concept:C0031525 | lld:lifeskim |
| pubmed-article:12637317 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12637317 | pubmed:dateCreated | 2003-6-19 | lld:pubmed |
| pubmed-article:12637317 | pubmed:abstractText | Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-alpha were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21 evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission. | lld:pubmed |
| pubmed-article:12637317 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12637317 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12637317 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12637317 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12637317 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12637317 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12637317 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12637317 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12637317 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12637317 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12637317 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12637317 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:FaderlStefanS | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:FreireichEmil... | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:KantarjianHag... | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:Garcia-Manero... | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:TalpazMosheM | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:O'BrienSusanS | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:ThomasDeborah... | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:VerstovsekSrd... | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:CortesJorgeJ | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:RiosMary... | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:FerrajoliAles... | lld:pubmed |
| pubmed-article:12637317 | pubmed:author | pubmed-author:GilesFrancisF | lld:pubmed |
| pubmed-article:12637317 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12637317 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:12637317 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:12637317 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12637317 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12637317 | pubmed:pagination | 83-6 | lld:pubmed |
| pubmed-article:12637317 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:meshHeading | pubmed-meshheading:12637317... | lld:pubmed |
| pubmed-article:12637317 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12637317 | pubmed:articleTitle | Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. | lld:pubmed |
| pubmed-article:12637317 | pubmed:affiliation | Department of Leukemia and Bioimmunotherapy, M. D. Anderson Cancer Center, University of Texas-Houston, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA. jcortes@mdanderson.org | lld:pubmed |
| pubmed-article:12637317 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12637317 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12637317 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12637317 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12637317 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12637317 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12637317 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12637317 | lld:pubmed |
